Alain Bergeron
Chercheur universitaire
Axe Oncologie
Publications
View all-
article Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Netwo…
Eur Urol Oncol 2025.
-
article Laaraj J, Lachance G, Bergeron A, Fradet Y, Robitaille K, Fradet V
New insights into gut microbiota-prostate cancer crosstalk
Trends Mol Med 31 (9), 2025.
-
article Xu X, Zhu H, Hugh-White R, Livingstone J, Eng S, Zeltser N, Wang Y, Pajdzik K, Chen S, Houlahan KE, Luo W, Liu S, Sheng M, Guo WY, Arbet J, Song Y, Wang M, Zeng Y, Wang S, Zhu G, Gao T, Chen W, Ci X, Xu W, Xu K, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Têtu B, Fradet Y, Lupien M, Wei GH, Koritzinsky M, Bristow RG, Fleshner NE, Wu X, Shao Y, He C, Berlin A, van der Kwast T, Leong H, Boutros PC, He HH
The landscape of N6-methyladenosine in localized primary prostate cancer
Nat Genet 57 (4), 2025.
Projects
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2027-07-31
- Repurposing 5-alpha reductase inhibitors to improve outcomes for bladder cancer patients, from 2025-10-01 to 2030-09-30
- En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16